Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. reports developments as a clinical-stage biopharmaceutical company developing medicines for serious infectious diseases and cancer. Recurring updates cover its chronic hepatitis delta program, including the investigational combination of tobevibart and elebsiran, and its oncology portfolio of PRO-XTEN® dual-masked T-cell engagers across solid tumor targets.
Company news also includes clinical data presentations, trial progress, financial results, equity financing activity, and strategic collaborations. Its VIR-5500 program is a PSMA-targeted PRO-XTEN® dual-masked T-cell engager for metastatic prostate cancer, and the company also describes preclinical work across infectious diseases and oncologic malignancies.
Vir Biotechnology announced that the European Association for the Study of the Liver (EASL) Congress 2024 has upgraded its Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The presentation will take place on June 8 during the EASL Congress in Milan, Italy, which runs from June 5-8. The company will also host an investor call on June 5 to discuss the new SOLSTICE data, including 12-week and 24-week treatment outcomes. Additional 48-week data on the efficacy and safety of tobevibart and elebsiran will be provided, complementing data shared at the 2023 AASLD Liver Meeting.
Brii Biosciences announced that the National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designations for two of its investigational therapies: BRII-877 (tobevibart) and BRII-835 (elebsiran). These therapies target hepatitis B virus (HBV) and are supported by extensive Phase 1 and 2 studies. BRII-877 has treated over 350 patients, showing well-tolerated results and significant decreases in HBsAg levels. BRII-835, studied in over 570 patients, demonstrated robust antiviral activity against HBV. These designations bolster Brii Bio’s ongoing efforts to develop functional cures for chronic HBV and HDV infections, enhancing their therapeutic regimens to achieve higher cure rates in broader patient populations.
Vir Biotechnology provided a corporate update and reported financial results for the first quarter of 2024. They announced the acceptance of late-breaker SOLSTICE data abstract for poster presentation at the EASL Congress 2024, with two additional hepatitis program data readouts on track for the fourth quarter. The company had $1.51 billion in cash, cash equivalents, and investments as of March 31, 2024. Key pipeline programs include Chronic Hepatitis Delta and Chronic Hepatitis B, with abstracts accepted for poster presentation at the EASL Congress 2024. Additionally, the Company is advancing next-generation antibodies using its proprietary platform and expects to file multiple investigational new drug applications within the next 18 months.
Vir Biotechnology, Inc. (Nasdaq: VIR) CEO Marianne De Backer will participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on May 14. The event will be live webcasted and archived on the Vir website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.